<DOC>
	<DOCNO>NCT00024063</DOCNO>
	<brief_summary>RATIONALE : Drugs SU006668 may stop growth solid tumor stop blood flow tumor . PURPOSE : Phase I trial study effectiveness SU006668 treat patient advance solid tumor .</brief_summary>
	<brief_title>SU006668 Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose SU006668 patient advance solid tumor . II . Determine pharmacokinetics drug patient . III . Determine objective response patient treated drug . IV . Determine toxic effect drug patient . OUTLINE : This dose-escalation study . Patients receive oral SU006668 twice daily . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 6 12 patient receive escalate dos SU006668 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 4 12 patient experience dose-limiting toxicity . Patients follow 30 day every 3 month thereafter . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Orantinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow advanced malignancy : Breast Colorectal Nonsmall cell lung Gastric Pancreatic Renal Prostate Myeloma Failed standard therapy OR No effective standard therapy exist Measurable evaluable disease No known CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2.0 mg/dL AST ALT great 3 time upper limit normal Renal : Creatinine great 2 mg/dL OR Creatinine clearance least 40 mL/min Cardiovascular : No myocardial infarction severe/unstable angina within past 6 month No evidence uncompensated coronary artery disease electrocardiogram physical exam Other : No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No insulindependent diabetes mellitus No noninsulindependent diabetes mellitus clinical evidence severe peripheral vascular disease diabetic ulcer No manifestation malabsorption due prior surgery , GI disease , unknown reason No active inflammatory bowel disease No know intolerance excipients study drug formulation No acute chronic medical psychiatric condition laboratory abnormality would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior anticancer biologic immunotherapy recover No prior SU006668 No concurrent immunotherapy Chemotherapy : At least 4 week since prior anticancer chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy No concurrent hormonal therapy except hormonal contraception appetite stimulation Radiotherapy : Recovered prior radiotherapy Surgery : At least 6 week since prior surgery At least 6 month since prior coronary/peripheral artery bypass graft surgery Prior major GI surgery allow residual syptomatic manifestation malabsorption No prior organ transplantation Other : At least 4 week since prior investigational agent No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>